Formosa Pharmaceuticals (TPE:6838) Other Stockholders Equity: NT$-95.74 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6838 Formosa Pharmaceuticals Inc TPE:6838
49 GF Score
Price NT$22.80
GF Value NT$14.27
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Formosa Pharmaceuticals Other Stockholders Equity?

Formosa Pharmaceuticals TPE:6838 -5.00% 49 Other Stockholders Equity is NT$-95.74 Mil as of Dec. 2025. GuruFocus rates TPE:6838 with a GF Score™ of 49/100 and a GF Value™ of NT$14.27 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Formosa Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$-95.74 Mil.

Formosa Pharmaceuticals's quarterly Other Stockholders Equity increased from Jun. 2025 (NT$-91.27 Mil) to Sep. 2025 (NT$-90.31 Mil) but then declined from Sep. 2025 (NT$-90.31 Mil) to Dec. 2025 (NT$-95.74 Mil).

Formosa Pharmaceuticals's annual Other Stockholders Equity declined from Dec. 2023 (NT$-29.91 Mil) to Dec. 2024 (NT$-87.59 Mil) and declined from Dec. 2024 (NT$-87.59 Mil) to Dec. 2025 (NT$-95.74 Mil).

Formosa Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Formosa Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formosa Pharmaceuticals Other Stockholders Equity Chart

Formosa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -14.53 -18.14 -29.91 -87.59 -95.74

Formosa Pharmaceuticals Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.59 -85.93 -91.27 -90.31 -95.74
TPE:6838
49GF Score
Formosa Pharmaceuticals Inc TPE:6838
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formosa Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-95.74 Mil mean?
Formosa Pharmaceuticals (TPE:6838) has a Other Stockholders Equity of NT$-95.74 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Formosa Pharmaceuticals and its competitors.
Is Formosa Pharmaceuticals' Other Stockholders Equity too high?
Formosa Pharmaceuticals' current Other Stockholders Equity is NT$-95.74 Mil. Overall, Formosa Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' Other Stockholders Equity compare to VRTX and REGN?
Formosa Pharmaceuticals' Other Stockholders Equity of NT$-95.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Formosa Pharmaceuticals and its competitors. Formosa Pharmaceuticals's current Other Stockholders Equity is NT$-95.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.27, compared to a current price of NT$22.80 — trading 59.8% above its estimated fair value. The current Other Stockholders Equity is NT$-95.74 Mil. Formosa Pharmaceuticals' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current Other Stockholders Equity is NT$-95.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?

Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be overvalued. The current stock price of NT$22.80 is trading 59.8% above its estimated GF Value™ of NT$14.27. GuruFocus considers Formosa Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TPE:6838:

  • Other Stockholders Equity: NT$-95.74 Mil
  • GF Value™: NT$14.27 vs. price of NT$22.80 (59.8% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formosa Pharmaceuticals Business Description

Address No. 57, Fuxing North Road, 8th Floor-6, Songshan District, Taipei, TWN, 105
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
49GF Score

Get the complete analysis for TPE:6838

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.80
Price
NT$14.27
GF Value